Characterization and functional evaluation of JS207, a novel bispecific antibody against human PD-1 and VEGFA
1. 请及时下载文件确认是否正确, 系统将在 2025-10-20 09:43:14 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
S Lin, M Hong, J Zhang, W Zhao, K Li, C Wu…
Frontiers in …, 2025
frontiersin.org
Introduction Cancer immunotherapy has been revolutionized by targeting PD-1 to restore antitumor T-cell activity and blocking VEGF to attenuate immunosuppressive tumor angiogenesis. While combining PD-1 and VEGF inhibition has shown promise in enhancing antitumor responses, co-administration of two or more monoclonal antibodies face several challenges, including distinct pharmacokinetics, complex dosing, and toxicity. A bispecific antibody (BsAb) targeting both PD-1 and VEGF pathways could overcome these limitations …
